What is Raymond James’ Forecast for TSE:PRN FY2024 Earnings?

Profound Medical Corp. (TSE:PRN) – Research analysts at Raymond James increased their FY2024 EPS estimates for Profound Medical in a research note issued to investors on Tuesday, February 18th. Raymond James analyst M. Freeman now forecasts that the company will earn ($1.68) per share for the year, up from their previous estimate of ($1.79). Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical’s Q4 2024 earnings at ($0.37) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.24) EPS and FY2028 earnings at $1.62 EPS.

Profound Medical Stock Performance

Shares of PRN stock opened at C$10.60 on Thursday. The company has a debt-to-equity ratio of 20.05, a current ratio of 6.12 and a quick ratio of 14.98. The company’s fifty day moving average price is C$10.03 and its two-hundred day moving average price is C$10.83. The firm has a market capitalization of C$223.36 million, a P/E ratio of -5.50 and a beta of 0.81. Profound Medical has a 12 month low of C$7.90 and a 12 month high of C$15.75.

Insiders Place Their Bets

In other news, Director Arun Menawat Dr. purchased 20,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was acquired at an average cost of C$10.65 per share, for a total transaction of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was acquired at an average cost of C$10.65 per share, with a total value of C$141,996.45. 8.62% of the stock is owned by company insiders.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.